SAN FRANCISCO, July 7, 2015 /PRNewswire/ - goBalto, Inc., the leading provider of cloud-based clinical study startup solutions, announced today its latest version of goBalto Activate. The second major release of 2015 offers new features that further accelerate clinical study startup.
"There is intense pressure to speed clinical trials and restrain costs, with Sponsors and CROs continuing to search for ways to automate and reduce the time it takes to get investigative sites up and running," said Sujay Jadhav, goBalto's CEO. "goBalto is the industry standard for study startup, completing the eClinical Stack with full integration to existing CTMS and eTMF systems, enabling business process optimization, oversight and continual process improvements that existing systems don't address."
"The clinical trials industry recognizes that study startup is one of the most difficult areas today resulting in delays and high costs. Our initial research in this area shows that the study startup process is very unsophisticated and inefficient," said Ken Getz, Director, Tufts Center for the Study of Drug Development. "Sponsor organizations are typically struggling to identify and engage a global community of investigative sites quickly; to review and approve regulatory documentation in a timely manner; to manage costs, resources and timelines."
With over 2,000 pharmaceutical and CRO users in more than 60 countries using Activate to manage, track, and complete study startup tasks, goBalto has the largest industry-proven set of country workflows. Our standard 'out-of-the-box' country specific regulatory business process workflows allow quick site activation, leading to greater cost savings and faster market entry, making valuable therapies available to patients sooner.
"This release illustrates our commitment to our customers as we continue to support them accelerate the development of drugs that save lives and improve the quality of life," said Jadhav. "We now service three of the top 5 CROs and more than two-thirds of the top 20 pharma's, managing their clinical trial documents globally."
Activate customers report improved business performance and a reduction in cycle times by > 30%. New capabilities just released aim to improve project management capabilities and usability, with a focus on enhanced risk management, utilization, business process improvement, and administration. Activate's new features include:
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.